Education
About Us
Working with TipRanks
Follow Us
Sun Pharma Advanced Research Co. Ltd. (IN:SPARC)
:SPARC
SPARC Stock Chart & Stats
₹135.70
-₹2.58(-1.32%)
At close: 4:00 PM EST
₹135.70
-₹2.58(-1.32%)
Day’s Range― - ―
52-Week Range₹116.20 - ₹204.25
Previous CloseN/A
Volume383.41K
Average Volume (3M)24.00K
Market Cap
₹37.94B
Enterprise Value₹42.13B
Total Cash (Recent Filing)₹30.00M
Total Debt (Recent Filing)₹4.17B
Price to Earnings (P/E)―
Beta1.65
Next Earnings
May 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)-21.89
Price to Sales (P/S)66.17
P/FCF Ratio-12.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Out-licensing / Partnership Revenue ModelAn out-licensing and partnership model lets SPARC monetize successful R&D without bearing full commercialization capital. Milestones, development payments and royalties create durable, non-linear upside tied to partner-driven commercialization, reducing long-term capital intensity for the company.
Focused Novel & Specialty R&D CapabilityA concentrated focus on novel and specialty therapeutics builds deep scientific expertise and IP over time. This specialization raises barriers to entry, increases the chance of high-value NCEs, and supports sustained licensing value if candidates progress through clinical milestones and attract partners.
Improving Gross Margin TrendsRecent gross margin improvements suggest better product mix or cost discipline, which are necessary foundations for sustainable profitability. If maintained, higher gross margins reduce the cash burn required per R&D milestone and improve the company’s ability to fund further development or attract partners.
Bears Say
Negative Shareholders' Equity / High LeverageNegative equity and high leverage materially weaken financial flexibility. This constrains the company’s ability to fund clinical programs, borrow on favorable terms, or absorb setbacks, raising structural solvency and execution risk over the medium term absent material capital infusions or partner-funded development.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flows force reliance on external financing or licensing receipts. This ongoing cash burn threatens program continuity, can dilute existing shareholders through financings, and places pressure on management to secure deals rather than optimize long-term value creation.
Inconsistent Revenue And Persistent LossesChronic operating losses and declining or volatile revenue undermine the company’s ability to demonstrate commercial traction. Without consistent revenue from partners or launches, the firm faces sustained profitability risk and reduced negotiating leverage when seeking licensing deals or financings.
Sun Pharma Advanced Research Co. Ltd. News
SPARC FAQ
What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹116.20 and its highest was ₹204.25 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹37.94B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date is May 25, 2026 which is in 70 days.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on Feb 09, 2026. The company reported -₹2.478 earnings per share for the quarter, missing the consensus estimate of N/A by -₹2.478.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of -₹2.478 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.755%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
Technical Analysis
Aarti Drugs Limited
―
RPG Life Sciences Limited
―
Supriya Lifescience Limited
―
Suven Life Sciences Limited
―
Thyrocare Technologies Ltd
―